Malaria in Pregnancy

Ebako Ndip Takem¹ and Umberto D’Alessandro¹,²

¹Medical Research Council Unit, Fajara, The Gambia
²Institute of Tropical Medicine, Antwerp, Belgium

Correspondence to: Prof. Umberto D’Alessandro, Institute of Tropical Medicine, Antwerp, Belgium. E-mail: udalessandro@mrc.gm

Competing interests: The authors have declared that no competing interests exist.

Abstract. Pregnant women have a higher risk of malaria compared to non-pregnant women. This review provides an update on knowledge acquired since 2000 on P. falciparum and P. vivax infections in pregnancy. Maternal risk factors for malaria in pregnancy (MiP) include low maternal age, low parity, and low gestational age. The main effects of MiP include maternal anaemia, low birth weight (LBW), preterm delivery and increased infant and maternal mortality. P. falciparum infected erythrocytes sequester in the placenta by expressing surface antigens, mainly variant surface antigen (VAR2CSA), that bind to specific receptors, mainly chondroitin sulphate A. In stable transmission settings, the higher malaria risk in primigravidae can be explained by the non-recognition of these surface antigens by the immune system. Recently, placental sequestration has been described also for P. vivax infections. The mechanism of preterm delivery and intrauterine growth retardation is not completely understood, but fever (preterm delivery), anaemia, and high cytokines levels have been implicated.

Clinical suspicion of MiP should be confirmed by parasitological diagnosis. The sensitivity of microscopy, with placenta histology as the gold standard, is 60% and 45% for peripheral and placental falciparum infections in African women, respectively. Compared to microscopy, RDTs have a lower sensitivity though when the quality of microscopy is low RDTs may be more reliable.

Insecticide treated nets (ITN) and intermittent preventive treatment in pregnancy (IPTp) are recommended for the prevention of MiP in stable transmission settings. ITNs have been shown to reduce malaria infection and adverse pregnancy outcomes by 28-47%. Although resistance is a concern, SP has been shown to be equivalent to MQ and AQ for IPTp. For the treatment of uncomplicated malaria during the first trimester, quinine plus clindamycin for 7 days is the first line treatment and artesunate plus clindamycin for 7 days is indicated if this treatment fails; in the 2nd and 3rd trimester first line treatment is an artemisinin-based combination therapy (ACT) known to be effective in the region or artesunate and clindamycin for 7 days or quinine and clindamycin. For severe malaria, in the second and third trimester parenteral artesunate is preferred over
quarine. In the first trimester, both artesunate and quinine (parenteral) may be considered as options. Nevertheless, treatment should not be delayed and should be started immediately with the most readily available drug.

**Introduction**

**Epidemiology.** Malaria in pregnancy (MiP) is a major public health problem in endemic countries. There is a wealth of evidence showing that the risk of malaria (both infection and clinical disease) is higher in pregnant than in non-pregnant women, possibly due to the immunological, hormonal changes or other factors occurring during pregnancy. Most of the available evidence is on *Plasmodium falciparum* and *P. vivax*, though for the latter, there is much less information than for *P. falciparum*, while little is known on *P. ovale* and *P. malariae*, the other two human malaria species. This review will focus on *P. falciparum* and *P. vivax*, with the objective of providing an update on the recently acquired knowledge (since the year 2000).

**Burden.** Where transmission is stable and relatively high, mainly in sub-Saharan Africa, adults have acquired immunity against malaria, including pregnant women who, despite the immune tolerance occurring during pregnancy, are able to control but not clear malaria infections. Therefore, in this high risk group, asymptomatic infections are common while clinical malaria is relatively rare. A recent review of studies, carried out in sub-Saharan Africa between 2000 and 2011, reports that malaria prevalence in pregnant women attending antenatal clinics was 29.5% (95%CI: 22.4 - 36.5) in East and Southern Africa, and 35.1% (95%CI: 28.2-41.9) in West and Central Africa, while the prevalence of placenta malaria was 26.5% (95%CI: 16.7-36.4) in East and Southern Africa, and 38% (95%CI: 28.4-47.6) in West and Central Africa. More recently (studies published since 2008), the reported malaria prevalence (by microscopy unless specified otherwise) was lower, reflecting the recent decrease in malaria transmission observed in several African countries (Table 1). Most of the prevalence estimates were done by microscopy and they would probably be higher if more sensitive methods like PCR or placental histology were used. In addition, blood samples were collected at different times during pregnancy, increasing the difficulty of comparing different estimates.

In areas of low, unstable malaria transmission, mainly Asia-Pacific region and South America, pregnant women have a lower acquired immunity and malaria infections are more likely to evolve towards clinical disease. The number of pregnancies occurring in these areas has been estimated at 70.5 million in 2007. In the Asia-Pacific region, the median proportion of women with peripheral infection has been estimated at 15.3% and that of placenta malaria at 11%. For South and Central America, less data on the

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>N</th>
<th>Parasite prevalence</th>
<th>Trimester</th>
<th>Diagnosis</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>peripheral</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>2006-2008</td>
<td>1034</td>
<td>39.2 a</td>
<td>1-3</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Nigeria [19]</td>
<td>2008-2010</td>
<td>396</td>
<td>18 b</td>
<td>2,3</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Benin [30]</td>
<td>2000-2002</td>
<td>982</td>
<td>11.5 i</td>
<td>1,2</td>
<td>M, RDT, H</td>
<td>F</td>
</tr>
<tr>
<td>Ghana [90]</td>
<td>2000-2003</td>
<td>956</td>
<td>32, 38, 56 i</td>
<td>3</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Ghana [27]</td>
<td>2004</td>
<td>363</td>
<td>28.40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burkina [49]</td>
<td>1987-1988</td>
<td>1400</td>
<td>5-11 i</td>
<td>3</td>
<td>M</td>
<td>F &gt;90%</td>
</tr>
<tr>
<td>Tanzania [144]</td>
<td>2003-2004</td>
<td>413</td>
<td>8%</td>
<td>1,2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cameroon [22]</td>
<td>1996-1998</td>
<td>278</td>
<td>22.6, 76.1 i</td>
<td>26.8, 52.9</td>
<td>M, PCR</td>
<td>F, others</td>
</tr>
<tr>
<td>The Gambia [54]</td>
<td>2002-2004</td>
<td>783</td>
<td>9.5</td>
<td></td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>Cameroon [71]</td>
<td>2002</td>
<td>175</td>
<td>25.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Senegal [72]</td>
<td>2002</td>
<td>304</td>
<td>33.2</td>
<td></td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>Cameroon [34]</td>
<td>1998-2000</td>
<td>1143</td>
<td>44.7</td>
<td>44.7</td>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Cameroon [51]</td>
<td>1999-2001</td>
<td>770</td>
<td>32.8</td>
<td>33.7</td>
<td>M</td>
<td></td>
</tr>
<tr>
<td>Angola [145]</td>
<td>2008</td>
<td>679</td>
<td>10.9</td>
<td>1-3</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Burkina [29]</td>
<td>2003</td>
<td>295, 288</td>
<td>11.9, 32.2 i</td>
<td>1-3</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Gabon [31]</td>
<td>1995-1996</td>
<td>311</td>
<td>57</td>
<td></td>
<td>M</td>
<td>F</td>
</tr>
</tbody>
</table>

* F= *Plasmodium falciparum*; M: Microscopy; H: Histology; a incidence in per thousand women months; b peripheral and placental; c microscopy, RDT and PCR respectively; d according to trimester; e based on histology (primigravidae-multigravidae); f microscopy, PCR; g peripheral and placental; h RDT; i 80/696; j dry season, transmission season

Table 1. Burden of malaria in pregnancy in sub-Saharan Africa

---

Mediterr J Hematol Infect Dis 2013; 5; Open Journal System
burden of malaria in pregnancy is available (Table 2). In Peru, the cumulative incidence of clinical malaria in pregnant women for the period January-August 2004 and 2005 was 43.1% as compared to 31.6% in non-pregnant women. This study also suggested that subclinical malaria infections may occur frequently among pregnant women in this region, despite the relatively low transmission, and that passive surveillance, i.e. data collection at health facilities, may underestimate the actual burden of MiP. In Colombia, the prevalence of malaria among parturient women attending the local hospital was 13% when determined by microscopy and 32% by PCR. In the same study, the prevalence of placenta malaria was 9% by microscopy and 26% by PCR, while 2% and 13% of cord blood samples were positive by microscopy and PCR, respectively.

### Risk Factors

Maternal factors associated with the risk of malaria in pregnancy include maternal age, parity and gestational age. It is well established that younger women (primigravidae and multigravidae), particularly adolescents, are at higher risk of malaria infection than older women, and this is independent of parity. Parity also affects the risk of malaria as primigravidae are at higher risk than multigravidae, though less in low transmission settings, while in epidemic areas, the risk is not affected by parity. Most of the available data on malaria relate to the second and third trimesters. The peak of malaria prevalence seems to occur during the second trimester. Studies on malaria burden in the first trimester of pregnancy are scarce, but it is believed that the rates are similar to that of the second trimester. However, considering the difficulty of collecting this information (pregnant women start to attend the antenatal clinic after the first trimester), and of determining the gestational age with accuracy, it is unclear whether the risk starts to increase towards the end of the first trimester. Indeed, in Burkina Faso, malaria prevalence was higher during the first as compared to the second and third trimesters.

### Effects of Malaria Infection

The effect of malaria infection during pregnancy will depend on the degree of acquired immunity, which in turn depends on the intensity of transmission.

#### Maternal effects

Where transmission is stable, such as in most of sub-Saharan Africa, most infections are asymptomatic but increase substantially the risk of anaemia. This occurs over a background of physiological anaemia of pregnancy due to increased blood volume. Both symptomatic and asymptomatic infections can cause anaemia. Severe anaemia is more often observed in stable transmission settings, and more in primigravidae than in multigravidae. Malaria infections in the first or second trimester of pregnancy increase the risk of anaemia, though one study reported an increased risk also for infections occurring in the third trimester. Preventing malaria infection by intermittent preventive treatment during pregnancy (IPTp) reduces the risk of anaemia.

Where malaria transmission is unstable, malaria can cause maternal anaemia more in primigravidae than in multigravidae and for falciparum infections more than for vivax infections. Nevertheless, severe anaemia is less common in these settings. In places where malaria transmission is stable, little is known on the importance of malaria infection as a cause of miscarriage. Where malaria transmission is unstable, malaria as a cause of miscarriage seems more common, as the majority of infections evolve towards a clinical attack with fever, which may by itself determine miscarriage. Indeed, non malarial fevers also independently increase the risk of miscarriage. Nevertheless, asymptomatic infections, i.e. slide

### Table 2. Malaria burden in pregnancy in Asia-Pacific and South America

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>N</th>
<th>Parasite prevalence</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
<th>Parasite</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>peripheral</td>
<td>placenta</td>
<td>trimester</td>
<td>diagnosis</td>
<td>species</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand[42]</td>
<td>1986-2010</td>
<td>17613</td>
<td>5*</td>
<td>1</td>
<td>M</td>
<td>F, V</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>India[20]</td>
<td>2006-2007</td>
<td>2386718</td>
<td>1.8</td>
<td>2.4</td>
<td>2.3</td>
<td>M, RDT</td>
<td>F, V, mixed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venezuela[40]</td>
<td>200-2002</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand[81]</td>
<td>1995-2002</td>
<td>204</td>
<td>96.0*</td>
<td>6.9%</td>
<td>1.2,3</td>
<td>M</td>
<td>F, V, mixed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil[146]</td>
<td>1997</td>
<td>195</td>
<td>67.7*</td>
<td>29.7</td>
<td></td>
<td>F, V, mixed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand[39]</td>
<td>1993-1996</td>
<td>1459</td>
<td>37</td>
<td>1,2,3</td>
<td>M</td>
<td>F, V, mixed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia[141]</td>
<td>2004-2010</td>
<td>4478</td>
<td>19</td>
<td>2,3</td>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia[17]</td>
<td>2001</td>
<td>193</td>
<td>56.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peru[73]</td>
<td>2004</td>
<td>193</td>
<td>1* 6.6</td>
<td>0.53 5.17</td>
<td>M, PCR</td>
<td>F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* F=Plasmodium falciparum; V= Plasmodium vivax; M: Microscopy, H: Histology; a Antenatal clinics, delivery units; b vivax, falciparam-pregnant women were symptomatic (fever); c microscopy; d microscopy, PCR; *estimated from table; e estimated from data presented in paper (175/402)
confirmed malaria with no history of fever in the previous 48 hours and temperature <37.5 °C, was also associated with miscarriage.

Maternal mortality associated to malaria is probably under-reported. Malaria was an important cause of maternal death in some studies, while in others it was not as frequent. The substantial reduction in maternal mortality observed in Thailand after the implementation of early detection and treatment of malaria suggests that malaria is an important contributor to maternal mortality. When not a direct cause of death (severe malaria), malaria in pregnancy is often reported as co-morbidity, e.g. with eclampsia, in conditions associated with maternal mortality.

**Perinatal effects.** Malaria increases the risk of low birth weight (LBW) particularly in primigravidae, and this risk seems to be higher for infections in first or second trimester, though in one study this was true also for infections occurring late in pregnancy. In high malaria transmission settings, such an effect is due to intrauterine growth retardation (IUGR) rather than pre-term delivery, as most infections are asymptomatic. A meta-analysis of 32 cross-sectional data in Africa, showed malaria prevention in pregnancy is associated with 21% (95% CI=14-27) reduction in LBW.

In unstable transmission settings, preterm deliveries, stillbirths and neonatal deaths have been associated with malaria. P. vivax infections are also associated with LBW, and this effect appears to be similar in all pregnancies. In women with a single infection of P. vivax or P. falciparum detected and treated in the first trimester, no significant effect on gestation or birth weight was observed compared to women who also attended in the first trimester but who never had malaria detected in pregnancy.

**New born and infant effects.** Fewer studies on malaria in pregnant women have evaluated infant outcomes. Congenital malaria can occur in the neonatal period and can contribute to infant morbidity and mortality. Placenta malaria, especially active infection, has been linked to neonatal and infant mortality. A recent study in The Gambia has showed that malaria infection during pregnancy influences infant’s growth, independently of LBW. It also increases the risk of infant’s death and perinatal mortality, by causing LBW. This is confirmed by the reduction neonatal mortality, up to 60%, observed after the implementation of preventive interventions targeted to pregnant women, e.g. intermittent preventive treatment. In primi- and secundigravidae, malaria prevention with IPTp or insecticide-treated bed nets was significantly associated with a 18% decreased risk of neonatal mortality.

**Later childhood, adolescence and adulthood effects.**

The long term effects of malaria in pregnancy have not been studied. However, malaria causes IUGR leading to LBW, which may be related to diseases occurring during adulthood, including some cancers and the metabolic syndrome.

**Pathophysiology.** Pregnant women are at higher risk of contracting malaria than non-pregnant women. This increased susceptibility can be explained by the immunological changes induced by pregnancy, by hormonal factors, and by the higher attractiveness of pregnant women to mosquitoes. In addition, P. falciparum -infected erythrocytes in pregnant women bind to specific receptors, i.e. chondroitin sulphate A (CSA), and sequester in the placenta. They rarely bind to the other two commonly described receptors in non-pregnant individuals, i.e. CD36 and the intracellular adhesion molecule (ICAM-1). In pregnancy, the parasite antigens expressed on infected erythrocytes are collectively known as variant surface antigen (VSA). The binding of the variant surface antigen (VAR2CSA) with chondroitin sulphate A has been implicated in the pathology of falciparum malaria in pregnancy. The VAR2CSA belongs to the family of the erythrocyte membrane protein (PfEMP1), is encoded by the var2csa gene and its expression has been described in pregnant women with falciparum malaria. Levels of anti-VAR2CSA specific IgGs increase with parity, cannot be found in men and are associated with a favourable pregnancy outcome. The antibody responses to VSA, cytokine responses such as Th1, Th2, interleukins, TNF and regulators, IFN gamma, and monocytes have been observed in pregnant women with malaria. Rosetting, a phenomenon consisting of parasite-free erythrocytes surrounding parasite-infected erythrocytes and commonly observed in non-pregnant individuals, has been implicated in the pathogenesis of severe malaria but is uncommon in pregnant women with falciparum malaria.

The sequestration of P. vivax in the placenta, though until recently thought not to occur, has been described with the involvement of ICAM-1 and CSA as receptors. The effects of hormonal changes on pregnancy associated malaria have been described in few studies and are subject to debate. Increased cortisol levels have been associated with increased risk of malaria in pregnant women.

The increased attractiveness of pregnant women to
mosquitoes may be explained by physiological and behavioural changes occurring during pregnancy. Physiological changes include increased exhaled breath and increased abdominal temperature that may render pregnant women more easily detectable by mosquitoes. Behavioural changes are represented by the fact that pregnant women urinate twice as frequently as non-pregnant women, resulting in an increased exposure to mosquito bites at night because they have to leave the protection of their bed nets.

Malaria-associated placental changes have been described for stable and unstable transmission settings. They include presence of parasites, inflammatory changes and hemozoin (pigment) deposition. Placental changes have been characterised into four levels, i.e. acute (parasites present, malaria pigment absent), chronic (parasites and malaria pigment present), past infection (no parasite but pigment present) and no infection (both parasites and malaria pigment absent). Recently, a 2-parameter grading system, distinguishing between inflammation and pigment deposition, has been proposed as it correlates with pregnancy outcomes, in both a stable transmission setting in Tanzania, and an unstable setting in Thailand.

It is unclear what the mechanism at the basis of malaria-related preterm delivery is, though fever, anaemia, and high levels of TNF alpha or interleukin 10 have been identified as important risk factors. LBW due to IUGR is associated with maternal anaemia and elevated levels of cytokines. Although the exact mechanism has not been elucidated, it appears to be due to chronic infections that cause reduced foetal circulation and placental insufficiency. Placental endocrine changes related to falciparum infection have been suggested as another possible mechanism leading to IUGR. P. vivax is different from P. falciparum as it infects immature erythrocytes (reticulocytes), limiting the parasite densities. In addition, it can relapse during pregnancy due to the activation of liver hypnozoites. Vivax parasites do not frequently express variant surface antigens, at the basis of placenta sequestration, so that this does not occur frequently. Therefore, P. vivax probably affects birth weight, and increases the risk of miscarriage and preterm birth through a systemic rather than a local effect. Nevertheless, the mechanisms at the basis of these observations are not completely understood.

Clinical Presentation

**Diagnosis.** The diagnosis of malaria in pregnancy is essential to prevent its deleterious effects to the mother and the foetus. Unfortunately, the clinical signs of malaria in pregnant women are usually non specific, and where transmission is stable, most infections are asymptomatic. Therefore, suspected malaria cases should be confirmed by parasitological diagnosis, usually by microscopy and/or rapid diagnostic tests. Nevertheless, other methods such as PCR and placental histology can be also used, though the latter can be done only after delivery so that it cannot be used for the management of infections occurring during pregnancy.

Microscopy is one of the most widely used methods for diagnosing malaria, including during pregnancy. It has some advantages such as the possibility of determining the parasite density and species. However, its major disadvantage, besides the need of a regular power supply, is its sensitivity, which cannot go below 10-15 parasites per µl. Therefore, a substantial proportion of infected pregnant women would not be detected because of extremely low parasite densities or of parasites sequestered in the placenta, though both conditions have deleterious effects on the mother’s and her offspring’s health.

Several studies have investigated the use of microscopy for the diagnosis of MiP in stable malaria transmission settings in Africa. When taking placenta histology as the reference test, the sensitivity of peripheral blood microscopy for _P. falciparum_ infections (4 studies) was 60% (95% CI=50-69) and that of placental microscopy 45% (95% CI=34-56).

In settings with unstable malaria transmission, there are few studies on the sensitivity of microscopy on peripheral blood collected during pregnancy. Rapid diagnostic tests (RDT), detecting circulating malaria antigens, can also be used. Generally, the sensitivity of RDTs for the diagnosis of malaria in pregnancy is lower than that of microscopy. However, the time needed for the diagnosis is shorter than for microscopy and the training required for their use is minimal. Although RDT can detect malaria antigens, they cannot estimate the parasite density. The sensitivity of RDT on peripheral blood using peripheral microscopy as a reference test is estimated at 81% (95% CI= 55-95), and the sensitivity of RDT on placental blood was 81% (95% CI= 62-92) using placental microscopy as the reference.

PCR, which detects parasite DNA, can also be used for the diagnosis of malaria infection but is not readily available in health facilities. In stable transmission settings, the sensitivity of PCR was >80% when using microscopy as the reference. PCR sensitivity has not been estimated against placental histology as reference test.

**Severe malaria.** Severe malaria in pregnancy is more common in unstable transmission settings because of the lower immunity pregnant women have. Generally, women in the second and third trimesters of pregnancy...
are at a higher risk of developing severe malaria compared to non-pregnant adults. In low transmission settings, severe malaria in pregnancy is usually associated with pulmonary oedema, hypoglycaemia and severe anaemia. Mortality in pregnant women with severe malaria and treated with either artemunate and quinine varied between 9% and 12%.92

Prevention and Treatment. Prevention. The most widely used interventions to prevent malaria in pregnancy are insecticide-treated bed nets (ITN), including Long-Lasting Insecticidal Nets (LLINs), and intermittent preventive treatment in pregnancy (IPTp).

While ITNs have shown a substantial reduction in malaria morbidity and mortality in children,93-95,96 in pregnant women, it has been associated with a decrease in maternal parasitaemia (38%), anaemia (41%) and LBW (28%),97 and 47% reduction in maternal anaemia.98 In one study, there was no evidence of a reduction in anaemia and parasitaemia.99

IPTp is the administration of therapeutic doses of an antimalarial, currently sulfadoxine-pyrimethamine (SP), at least twice during pregnancy, in the second and third trimester, irrespective of the presence of a malaria infection. The WHO recommends its use and many sub-Saharan African countries have included it in their malaria control program. In stable transmission settings, many trials have shown that SP given as IPTp is efficacious in preventing the adverse consequences of malaria during pregnancy (Table 3).100-104 However, SP resistance represents a major threat. A study in Benin has showed that, despite the presence of molecular markers of resistance, SP remained efficacious.105 This has been confirmed by a review reporting that IPTp with SP is effective up to a certain level of SP resistance.106 Nevertheless, finding an alternative to SP for IPTp is important. Adding amodiaquine to SP was efficacious but not better than SP alone.107 Mefloquine (MQ), thanks to its long elimination half-life, could be a good alternative to SP as it would provide a long post-treatment prophylactic period. Indeed, a trial in Benin showed that for IPTp MQ was as good as SP in preventing LBW. MQ was more efficacious than SP in preventing placental malaria, clinical malaria and maternal anaemia at delivery. However, MQ was less well tolerated than SP, potentially compromising its large scale use as IPTp.108-109

There is no evidence that one of the methods is better than the other110 and the combined use appears to be better than individual use.

A different approach is systematic screening for malaria infections at regular intervals and treatment of the positive women, which may be more appropriate in settings where malaria transmission is low and the risk of infection between antenatal visits is also low. It has already be shown to have similar protective efficacy than IPTp but additional trials for a more thorough evaluation of this intervention are probably needed.26 Due to drug resistant malaria, it has been the only form

Table 3. Trials on Intermittent Preventive Treatment in pregnancy

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>Trial arms</th>
<th>N</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uganda[110]</td>
<td>2004-2007</td>
<td>SP vs SP+ITN vs ITN+placebo</td>
<td>5775</td>
<td>No differences between treatment arms</td>
</tr>
<tr>
<td>Mali[100]</td>
<td>2006-2008</td>
<td>SP 3 vs 2 doses</td>
<td>814</td>
<td>SP3 vs SP: 50% reduction in placental parasitaemia, LBW, pre-term births</td>
</tr>
<tr>
<td>Ghana[107]</td>
<td>2004-2007</td>
<td>SP, AQ, SP+AQ</td>
<td>3643</td>
<td>No difference peripheral parasitaemia, adverse events more frequent with AQ</td>
</tr>
<tr>
<td>Benin[109]</td>
<td>2005-2008</td>
<td>MQ, SP</td>
<td>1601</td>
<td>No difference in LBW, MQ more efficacious than SP in preventing malaria, MQ had more adverse events</td>
</tr>
<tr>
<td>Burkina Faso [37] **</td>
<td>2004-2006</td>
<td>SP</td>
<td>1441</td>
<td>SP vs CQ decreased LBW by 50%, placental infection by 80%</td>
</tr>
<tr>
<td>Benin[108]</td>
<td>2005-2006</td>
<td>CQ, SP</td>
<td>1699</td>
<td>No reduction of LBW, anaemia at delivery and placenta malaria; 40% reduction incidence of clinical malaria</td>
</tr>
<tr>
<td>Mozambique[101]</td>
<td>2003-2005</td>
<td>SP, PB*</td>
<td>1030</td>
<td>PE 61.3% neonatal mortality</td>
</tr>
<tr>
<td>Mozambique*[57]</td>
<td>2003-2005</td>
<td>SP, PB*</td>
<td>1030</td>
<td>PE against anaemia: 49.5 SP vs CQ</td>
</tr>
<tr>
<td>Ghana[26]</td>
<td>2007-2008</td>
<td>IPTp-SP, IST</td>
<td>3333</td>
<td>No difference between study arms but increase in Hb after intervention</td>
</tr>
<tr>
<td>Nigeria[102]</td>
<td>2003-2005</td>
<td>SP, CQ</td>
<td>352</td>
<td>PE against anaemia: 49.5 SP vs CQ</td>
</tr>
<tr>
<td>Nigeria[103]</td>
<td>2002</td>
<td>SP, CQ-P</td>
<td>500</td>
<td>SP better than CQ-P</td>
</tr>
<tr>
<td>Mozambique[104]</td>
<td>2001-2002</td>
<td>SP vs??</td>
<td>600</td>
<td>Parasite prevalence SP 6.3% vs 13.6%, 2.4 vs 13.3, high loss to follow-up</td>
</tr>
</tbody>
</table>

*PB=placebo, SP=sulfadoxine-pyrimethamine, AQ=amodiaquine, CQ=chloroquine, P=pyrimethamine; 12-28 weeks; *SP2=2 doses of SP, SP0=no dose of SP; **maternal and birth outcomes up to 8 weeks have been reported in [101]; **community trial; PE=parasitological efficacy; IST: Intermittent Screening and Treatment
of malaria control on the Thai-Burmese border for more than 20 years, impacting significantly on maternal mortality rates.47

In future, vaccines specifically designed to prevent MiP may become available; VAR2CSA, in the early stages of development, seems the most promising candidate.111-116 However, there are still several uncertainties, including the number of antigenic variants to be combined for an optimal response, the timing of the vaccine, e.g. during pregnancy or at puberty, whether only first pregnancies should be targeted, and the length of follow up for children born to vaccinated mothers.111-112,117

Treatment. It is recommended that pregnant women with malaria are treated after parasitological confirmation of the diagnosis, reducing the unnecessary exposure to antimalarials of both the mother and the foetus.

First trimester. Clinical trials on the safety and efficacy of antimalarials in pregnancy usually exclude women in the first trimester of pregnancy so that the evidence is based on observational studies (Table 4). Artemisinin derivatives were relatively safe (n=1937) in the first trimester of pregnancy42,118-119 and the cumulative failure rate reported in only one study was 6.6% across all trimesters (n=461).118 No major adverse event was observed in 377 women with known pregnancy outcome and exposed to artemisinins in the first trimester.42,119-121 However, only 1 study120 out of 4, was a randomised controlled trial though the treatment was given during a mass campaign and the exposure was thus inadvertent; the birth weight of newborns delivered by women exposed to artesunate during the first trimester was similar to that of the other pregnant women. According to recommendations,88 chloroquine, quinine, clindamycin and proguanil can be considered safe in the first trimester.

In case of uncomplicated malaria in the first trimester, a combination of quinine + clindamycin for 7 days is recommended.

In case of severe malaria, parenteral antimalarials are recommended.88 In the first trimester, the risk of hypoglycaemia is lower and the uncertainties on the safety of the artemisinins derivatives are greater. Nevertheless, considering that treatment should not be delayed and that artesunate reduces the risk of death, both artesunate and quinine (parenteral) may be considered as options. Treatment should be started immediately with the most readily available drug.90

Second and third trimesters. There is more experience on the use of artemisinin derivatives in the second and third trimesters of pregnancy. Evidence is available from both trials122-127 and observational studies128-131 involving pregnant women (Table 4). Data available indicate that ACTs are relatively safe for the foetus when taken after the first trimester of pregnancy. A recent review of treatment studies carried out in pregnant women from 1998-2009, reported a parasitological failure >5% in 3 out of 11 trials.132 In the second trimester, ACTs that are known to be effective in the area, or 7 days artesunate+ clindamycin, or 7 days quinine+ clindamycin are recommended for uncomplicated malaria.88 In case of severe malaria, parenteral artesunate is preferable because it saves the life of the mother. Several studies have shown that the kinetics of artemisinins derivatives, most specifically of the active metabolite dihydroartemisinin, is modified during pregnancy.133-134

Amodiaquine (AQ) has been shown to be efficacious in pregnant women with falciparum malaria in Ghana and Tanzania.122,125 Day 28 parasitological failure rates were 3% for AQ monotherapy,122 0-1% for the combination AQ+SD,122,125 and 4.5% for the combination AS+AQ.125 It was relatively safe and well tolerated and associated with some minor side effects (nausea, weakness, dizziness). Blood dyscrasias were not a problem associated with its use. A pharmacokinetics study on AQ for treatment of P.vivax in pregnancy conducted in Thailand indicates the doses are similar to that of non-pregnant adults.131,135

There are fewer reports on the efficacy and safety of mefloquine (MQ) for MiP. High cure rates have been reported in Thailand, for the combination of MQ+AS (cure rate of 98.2% at day 63).126 One study reported minor side effects.109 However, there are concerns about still births and neuropsychiatric disorders. There are currently some ongoing clinical studies which will provide useful data on the safety, efficacy and pharmacokinetics of MQ in pregnant women (Table 5). The combination AS+ MQ is being evaluated in studies in Africa and Asia (NCT00852423, NCT00701961, NCT01054248, CTRI/2009/091/001055TEMP, NCT01054248).

In Uganda, in an area of relatively high transmission and hence with pregnant women having some acquired immunity, artemether-Lumefantrine (AL) was efficacious, with cure rates >95%.136-137 However, in Thailand the cure rate at day 42 was only 82%,138 possibly due to the low day 7 lumefantrine concentrations. AL was safe and well tolerated.136-138

As for other antimalarial treatments, pharmacokinetics may be altered during pregnancy, with plasma concentrations lower than expected.129,139 AL is currently being evaluated in Thailand and in four sites in sub-Saharan Africa (NCT01054248, NCT00852423).

Dihydroartemisinin piperazine (DHA-PQ) was highly effective in women with multiple recrudescen

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>Antimalarial</th>
<th>N</th>
<th>Trimester</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ghana[122]</td>
<td>2003-2004</td>
<td>CQ, AQ, SP, AQP, SP, CD, AS+AQ</td>
<td>900</td>
<td>2.3</td>
<td>Day 28 PF: CQ 14%, SP 11%, AQ 3%, AQ+ SP 0%.</td>
</tr>
<tr>
<td>Tanzania[125]</td>
<td>2004-2006</td>
<td>AQP, SP, AS+AQ</td>
<td>272</td>
<td>2.3</td>
<td>Day 28 PF: CD 18%, AS+SP 1%, AS+AQ 4.5%.</td>
</tr>
<tr>
<td>Uganda[137]</td>
<td>2006</td>
<td>AL, CD</td>
<td>114</td>
<td>2.3</td>
<td>Day 28 CR: AL 100% CD 100%.</td>
</tr>
<tr>
<td>Thailand[138]</td>
<td>2004-2006</td>
<td>AL, AS7</td>
<td>252</td>
<td>2.3</td>
<td>Day 42 or delivery CR: AS7 89.2%, AL 82%.</td>
</tr>
<tr>
<td>Thailand[123]</td>
<td>2001-2003</td>
<td>AAP, Q*</td>
<td>81</td>
<td>2.3</td>
<td>Day 63 CR: AAP 94.9%, Q 63.4%</td>
</tr>
<tr>
<td>Malawi[127]</td>
<td>2003-2004</td>
<td>SP, SP+AZ, SP+AS</td>
<td>141</td>
<td>2.3</td>
<td>PF: SP-AS 14.3%, 11.4%, 44.8 %, Recrudescence less frequent in SP-AS vs SP (HR 0.25)</td>
</tr>
<tr>
<td>Thailand[124]</td>
<td>1997-2000</td>
<td>QC7, AS7</td>
<td>129</td>
<td>2.3</td>
<td>both had 100% day 42 CR</td>
</tr>
<tr>
<td>Uganda*[128]</td>
<td>2008</td>
<td>A, DHA</td>
<td>21</td>
<td>2.3</td>
<td>PK concentrations A and DHA lower than non pregnant adults</td>
</tr>
<tr>
<td>Thailand[135]</td>
<td></td>
<td>AQ</td>
<td>27</td>
<td></td>
<td>AQ reduced recurrent infections from 22.2 to 7.4% day 35 for P. vivax, PK PD no adjustments of dose required</td>
</tr>
<tr>
<td>PNG [147]</td>
<td>2006</td>
<td>CQ for IPTp</td>
<td>30</td>
<td>2.3</td>
<td>Reduced plasma concentrations CQ and metabolite</td>
</tr>
<tr>
<td>Malawi, Mozambique, Sudan, Zambia[148]</td>
<td></td>
<td>SP for IPTp</td>
<td>97</td>
<td>2.3</td>
<td>PK Inconsistent changes in concentrations of S and P</td>
</tr>
<tr>
<td>Thailand b [129]</td>
<td>2004-2006</td>
<td>L in AL</td>
<td>103</td>
<td></td>
<td>PK: 40% low capillary concentrations</td>
</tr>
<tr>
<td>Thailand[131]</td>
<td></td>
<td>DHA+PQ</td>
<td>24</td>
<td></td>
<td>PK: Reduced exposure DHA, unaltered exposure PQ</td>
</tr>
<tr>
<td>Thailand[131]</td>
<td>2007-2008</td>
<td>AQ</td>
<td>24</td>
<td>2, 3</td>
<td>PK: Safe, similar pharmacokinetic properties with non pregnant</td>
</tr>
<tr>
<td>Thailand[139]</td>
<td>2004</td>
<td>AL</td>
<td>13</td>
<td>2, 3</td>
<td>PK: Reduced plasma concentrations of both A and L</td>
</tr>
<tr>
<td>Thailand[149]</td>
<td>1995-2000</td>
<td>Q-PF, CQ-PV</td>
<td>300</td>
<td>1</td>
<td>safe but more tinnitus and maternal anaemia for Q</td>
</tr>
<tr>
<td>Thailand[42] †</td>
<td>1986-2010</td>
<td>Q, CQ-PV, AS, MQ</td>
<td>17613</td>
<td>1</td>
<td>symptomatic malaria OR=3.99; no significant effect of drug on miscarriage or malformation rates perinatal mortality OR AL vs SP 0.84(0.45-1.53), no difference in maternal mortality, still birth, LBW; increase abortion rate AL.</td>
</tr>
<tr>
<td>Zambia[119]</td>
<td>2004-2008</td>
<td>AL, SP</td>
<td>1001</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

AS=sartemate, AQ=amodiaquine, AZ=Azithromycin, CD=chlorproguanil-dapsone, DHA=dihydroartemisinin, PQ=piperazine, CQ=chloroquine, L=lamefantrine, MQ=mefloquine, Q=quinine, SP=sulfadoxine-pyrimethamine; PF=parasitological failure; CR=cure rate; PE=parasitological efficacy; PK=pharmacokinetics; PNG=Papua New Guinea; *supervised quinine for 7 days; † peripheral microscopy, placental microscopy and placental histology; ‡ part of data in McGready 2001[118], Mc Gready 2002[149]; data from McGready 2008[138]; ‡ main trial Piola 2010[136]

Table 5. Registered ongoing trials on malaria treatment in pregnant women

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Registration ID</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective and safe treatment for malaria in pregnancy in India: a randomised controlled trial</td>
<td>India</td>
<td>CTRI/2009/091/0010 55TEMP</td>
<td>AS+SP, AS+MQ</td>
</tr>
<tr>
<td>Randomized trial of 3 artemisinin combination therapy for malaria in pregnancy (DAMA)</td>
<td>Thailand</td>
<td>NCT01054248</td>
<td>AS+MQ, AL, DHA+PQ</td>
</tr>
<tr>
<td>Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria (PREGACT)</td>
<td>Burkina Faso, Ghana, Malawi, Zambia</td>
<td>NCT00852423</td>
<td>DHA-PQ, AS+MQ, AS+AQ, AL</td>
</tr>
<tr>
<td>Pharmacokinetics of mefloquine-artesunate in Plasmodium falciparum malaria infection in pregnancy</td>
<td>Burkina Faso</td>
<td>NCT00701961</td>
<td>MQ-AS (pregnant vs. non-pregnant)</td>
</tr>
<tr>
<td>ACT in pregnant women: Efficacy, safety and tolerability of dihydroartemisinin-piperazine for treatment of uncomplicated malaria in pregnancy in Ghana</td>
<td>Nigeria</td>
<td>PACTR20100200018 62624</td>
<td>Experimental group: AS/AQ, control group AL</td>
</tr>
<tr>
<td></td>
<td>Ghana</td>
<td>NCT01231113</td>
<td>Drug: AS-AQ, Drug: DHA-PQ fixed-dose combination</td>
</tr>
</tbody>
</table>
infections on the Thai-Burmese border.\textsuperscript{140} DHA-PQ is used in the Western Pacific for malaria in pregnant women.\textsuperscript{141} DHA-PQ is currently being evaluated in 3 studies in Africa and Asia (NCT00852423, NCT01054248, NCT01231113). Cure rates and PK are reassuring.

In Thailand, atovaquone-proguanil in combination with artesunate (AAP) was associated with high cure rates (>95\%) and was relatively safe\textsuperscript{123,142} though the sample size was small. In Thailand, plasma concentrations of AAP were lower in pregnant than in non pregnant women.\textsuperscript{143}

Conclusions. This review shows that although the deleterious effects of MiP to both the mother and the child are well documented, the mechanisms involved are still relatively unknown, particularly where transmission is low and unstable. The diagnosis of MiP is challenging, as peripheral microscopy will miss a large proportion of infected women with parasites sequestered in the placenta. MiP can be prevented by currently available control methods, i.e. ITNs and IPTp, but the challenge is attaining a high coverage, particularly with women for the highest risk such as adolescent primigravidae. It is still unclear what would be the alternative to SP for the IPTp.

The burden of \textit{P. vivax} MiP, which is substantial in the Asia-Pacific region and in South America has been relatively neglected. It is generally believed that vivax infections are milder than falciparum ones, but this is based on few studies. There is also the need of having more sensitive diagnostic methods for vivax infections, as it would help improving early diagnosis and appropriate management. Finally, information of the safety and efficacy of antimalarials during pregnancy is growing, though this is true mainly for the second and third trimester. For the first trimester, treatment options are still extremely limited and evidence is mainly based on pharmacovigilance data on accidental exposures.

References:


stable malaria

05): 283

e pregnant women indicates ongoing

anti A, Bertin G, Dahlback M, Fievet N,

k WH, The ABO blood group system and

F receptors 1 and 2


la O, Me

43x51

47.

51.

52.

53.

54.

50.

47.

44.

43.

42.

41.

40.

39.

38.

37.

36.

35.

34.

33.

32.

31.

30.

29.

28.

27.

26.

25.

24.

23.

22.

21.

20.

19.

18.

17.

16.

15.

14.

13.

12.

11.

10.

9.

8.

7.

6.

5.

4.

3.

2.

1.

...


Mediterr J Hematol Infect Dis 2013; 5: Open Journal System

http://dx.doi.org/10.1093/cid/cir374 PMid:21765069


PMid:18274885


http://dx.doi.org/10.1007/s10995-008-0319-3 PMid:18274885


PMid:17556604


http://dx.doi.org/10.1111/j.1365-3156.2004.01307.x PMid:15482398


http://dx.doi.org/10.1186/1475-2875-10-196 PMid:21767415 PMCid:3199903


http://dx.doi.org/10.1001/jama.297.23.2603 PMid:17579229


http://dx.doi.org/10.1086/590114 PMid:18591809


PMid:18591809


http://dx.doi.org/10.1016/j.vaccine.2010.08.080 PMid:21075162


http://dx.doi.org/10.1086/324349 PMid:11712093


http://dx.doi.org/10.1186/1475-2875-9-249 PMid:20889964 PMCid:2944339


http://dx.doi.org/10.1046/j.1365-3032.2001.019004-4 x


http://dx.doi.org/10.1179/136485909X398283


http://dx.doi.org/10.1016/S0140-6736(06)65959-7


http://dx.doi.org/10.1086/403251 PMid:16088834


http://dx.doi.org/10.1046/j.1365-3032.2001.0190106-3


http://dx.doi.org/10.1371/journal.pone.0005138 PMid:19352498 PMCid:2662423

http://dx.doi.org/10.1016/S0395-9203(00)00235-9


